ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Aprea Therapeutics (APRE)
Aprea Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.52▲ +16.19%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Aprea Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Aprea Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Aprea Therapeutics a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.42 and $0.60; in 9 out of 10, between $0.31 and $0.81. Estimated annual volatility is 104%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $8.8M
- 52-week high
- $1.49
- 52-week low
- $0.41
- Revenue (12 months)
- $0.0M
- Return on equity
- -46.2%
- Free cash flow (12 months)
- $-8.2M
- Beta
- 1.63
What this means
ATLAS does not publish a fair value for APRE right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks APRE has traded between $0.41 and $1.49. Today it is 65.0% below that high and 27% above its low.
Its beta is 1.63: it tends to move more than the market, both up and down.
About the company
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers.
Want to see everything about Aprea Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Aprea Therapeutics do?
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers.
What is the chance APRE goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, APRE ends the month between $0.42 and $0.60.
How big is Aprea Therapeutics and what is its P/E ratio?
Aprea Therapeutics's market capitalization is $8.8M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is APRE?
ATLAS estimates annual volatility at 104%. In a typical month, half of the outcomes end between $0.42 and $0.60.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer